Cancer Advisor

Abstract Background: Precision oncology has traditionally relied on population-based evidence, yet tumor heterogeneity and dynamic resistance limit durable responses. N=1 adaptive strategies—where treatment is continuously tailored to an individual patient—represent a promising paradigm shift. Methods: We developed an in silico prospective cohort of 10 virtual patients with advanced KRAS-mutant non-small cell lung cancer (NSCLC). Each patient underwent iterative treatment guided by simulated circulating tumor DNA (ctDNA), imaging, and evolving tumor genomics. The adaptive cohort was compared against a simulated standard-of-care (SOC) arm consisting of chemotherapy ± Pembrolizumab. Primary endpoint was progression-free survival (PFS). Results: Median PFS improved from 7.8 months (SOC) to 17.6 months (adaptive N=1 strategy). Early ctDNA-guided intervention enabled detection of resistance approximately 8–10 weeks prior to radiographic progression, consistent with prior clinical observa...

Cancer remains one of the leading causes of death globally, but modern medicine offers a growing spectrum of interventions beyond the traditional “big three”: surgery, chemotherapy, and radiation. For patients seeking alternatives due to personal preference, comorbidities, or prior treatment experience, understanding which evidence-based strategies can support survival and quality of life is critical. This article examines the highest-quality data on non-surgical, non-chemotherapy, and non-radiation approaches, including precision and immune-based therapies, clinical trial options, and integrative strategies . We emphasize realistic expectations , differentiating interventions that can control disease versus those that are primarily supportive. 1. The Reality Check: Why Evidence Matters Multiple large studies, including analyses from Yale University and national cancer databases, consistently demonstrate that patients who refuse standard treatments in favor of alternative therapies a...